Should olanzapine (Zyprexa) be added as an adjunct to an antidepressant to treat residual depressive symptoms in an adult?

Olanzapine as Adjunct for Residual Depressive Symptoms in Major Depressive Disorder

Olanzapine (Zyprexa) should be considered as an adjunctive treatment to antidepressants for adults with treatment-resistant depression (TRD), specifically when patients have failed at least two adequate antidepressant trials, but this should be a time-limited intervention due to significant metabolic risks. 1

FDA-Approved Indication and Evidence Base

The combination of olanzapine and fluoxetine is FDA-approved for treatment-resistant depression, defined as major depressive disorder in patients who do not respond to 2 separate trials of different antidepressants of adequate dose and duration in the current episode 1. The approved dosing range is olanzapine 5-20 mg/day combined with fluoxetine 20-50 mg/day, with demonstrated efficacy at olanzapine 6-18 mg and fluoxetine 25-50 mg 1.

Key Clinical Considerations:

• Start with olanzapine 5 mg plus fluoxetine 20 mg once daily in the evening, adjusting according to efficacy and tolerability 1
• The combination produces rapid antidepressant effects compared to antidepressant monotherapy, with strongest effects when TRD is defined as failing at least two antidepressant trials 2
• Response rates in controlled trials show 50% response and 35.3% remission rates with olanzapine augmentation versus 20.6% response and 11.8% remission with placebo 3

When to Consider Olanzapine Augmentation

Olanzapine augmentation may be particularly beneficial for specific symptom profiles rather than routine use in all inadequate responders 4:

• Severe ruminations
• Melancholic features 5
• Major sleep disturbance
• Psychotic features (delusions or hallucinations) 6

This is NOT recommended for routine use in all patients with inadequate antidepressant response 4. The evidence supports short-term use in true treatment-resistant depression rather than first-line inadequate response 4.

Critical Safety Concerns and Monitoring

Metabolic Side Effects (Major Limitation)

Olanzapine carries significant metabolic risks that often outweigh benefits for long-term use 3:

• Weight gain: Significantly greater than antidepressant monotherapy and similar to olanzapine monotherapy 2
• Lipid changes: Increases in total cholesterol, triglycerides, and LDL cholesterol are greater than either olanzapine or fluoxetine alone 2, 3
• Glucose dysregulation: Increased risk requiring monitoring 3

Required Monitoring Protocol

Before initiating olanzapine augmentation, obtain 7:

• BMI and waist circumference
• Blood pressure
• HbA1c or fasting glucose
• Lipid panel
• Liver function tests

Repeat fasting glucose at 4 weeks, then BMI/waist circumference/blood pressure weekly for 6 weeks, with comprehensive metabolic panel at 3 months and annually 7.

Duration of Treatment

There is no support for long-term use of adjunctive olanzapine in unipolar depression 4. Most treatment guidelines are non-specific about duration but emphasize:

• Short-term use for acute symptom control 4
• Regular reassessment of need for continued therapy 1
• Attempts to taper when conditions allow 7

For bipolar depression (different indication), continuation for 9-12 months after recovery is recommended, but this does not apply to unipolar depression 7.

Alternative Sequencing in Treatment Algorithm

Current evidence-based guidelines recommend the following sequence for treatment-resistant depression 7:

1. First-line: Optimize current antidepressant dose, ensure adequate trial duration (6-8 weeks) 7
2. Second-line: Switch to different antidepressant class OR add evidence-based psychotherapy (CBT, interpersonal therapy) 7
3. Third-line: Consider adjunctive strategies including:
   • Different antidepressant augmentation
   • Psychotherapy if not already tried
   • Atypical antipsychotics (aripiprazole, quetiapine, or olanzapine) 7, 8

Olanzapine augmentation should generally be reserved for after other augmentation strategies have failed, given the metabolic burden 4.

Common Pitfalls to Avoid

• Do not use olanzapine for mild depressive symptoms or subsyndromal depression - antidepressants themselves are not recommended for mild depression 7
• Do not continue indefinitely without reassessment - the metabolic risks accumulate over time 4, 3
• Do not use full antipsychotic doses - subantipsychotic doses (5-20 mg) are required for antidepressant effect; higher doses are dysphorogenic 8
• Do not combine with benzodiazepines carelessly - fatalities have been reported with concurrent high-dose olanzapine and benzodiazepines 7
• Do not neglect metabolic monitoring - weight gain averaging 3-5 kg and lipid elevations occur in majority of patients 3

Bottom Line

Olanzapine augmentation is an evidence-based option for true treatment-resistant depression after multiple antidepressant failures, but should be time-limited and reserved for patients with specific symptom profiles (severe ruminations, melancholia, sleep disturbance) who can tolerate metabolic monitoring. The significant weight gain and metabolic side effects make this a third-line option after other augmentation strategies, and long-term use is not supported by evidence 4, 3.